Amgen lawsuit over cholesterol drug will get new trial
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Mannkind stock soars over new label info for Afrezza
Westlake Village biotech company Mannkind received approval to update the prescribing information for its inhalable insulin product, Afrezza, making it easier to market to customers. The new label information clarifies starting and adjusting mealtime dosages, as well as initial and peak effects, and helps the company avoid confusing language, CEO Michael Castagna said in a Read More →
GeoLinks using Silicon Valley-style office to attract employees
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
UCSB researchers get $9 million to develop new brain imaging
UC Santa Barbara researchers received $9 million to further their efforts to get a better view of the human brain. The National Science Foundation awarded the funding to the Next Generation Multiphoton Neuroimaging Consortium project, or NEMONIC, which includes UCSB researchers John Bowers, Michael Goard and Luke Theogarajan among its team of neuroscientists, electrical engineers, Read More →
CalAmp reports revenue decline but net income up
Information technology company CalAmp reported on Sept. 28 a slight drop in revenue for its second quarter but a dramatic increase in net income, bringing in $12.2 million, or 34 cents per share. The company, which has operations in Oxnard, brought in $89.8 million during the quarter, down slightly from $90.5 million in the second Read More →
Amgen settles with AbbVie over Humira biosimilar
Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →
Amgen agrees to develop biosimilars for Chinese market
Increasing its global footprint in the biosimilars market, Amgen announced Sept. 26 that it had formed an exclusive co-development agreement with Chinese drug manufacturer Simcere Pharmaceutical Group. The agreement aims to bring four oncology and inflammation biosimilars in Amgen’s portfolio to commercialization in China. The Thousand Oaks-based biotechnology company will produce and submit approval applications Read More →
